In this issue of Pain Medicine, the article "Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts," by Mr. Rose [1] , raises some interesting questions and apprehensions concerning the current policy on prescribing opioids for patients with chronic nonmalignant pain (CNMP). In his article, Mr. Rose challenges the validity of the data that have been employed to support the recommendations of current opioid prescribing guidelines and, in general, the wellpublicized and politically charged trepidations regarding a national "opioid epidemic." His main conclusion was to challenge the underlying assumptions about opioid analgesics with respect to lethality and efficacy. In his concluding remarks, he states, "Illicit fentanyl and heroin, not opioid prescribing, now fuel the current opioid overdose epidemic." He goes on further to say that this collective fear of a burgeoning opioid epidemic has "potentially devastating effects on uncontrolled chronic pain" and that legitimate pain patients who might benefit from opioid therapy cannot gain access due to this new guiding philosophy and adopted standard of care. In response to Mr. Rose's manuscript, Dr. Mark Sullivan [2] thoughtfully addressed the major tenants of Mr. Rose's arguments on the importance of more liberal access to opioid therapy for patients with CNMP and countered many of his opinions on the prevailing data that have guided the current state and national decision-making around opioid analgesic therapy.
While both perspectives have their own merit, there are clearly some significant methodological weaknesses in studies that support both points of view. For example, Mr. Rose cited a study by Alford et al. [3] in which 589 patients in a primary care clinic who tested positive for any illicit substances or prescription drug misuse were interviewed regarding pain, pain-related interference, and their reasons for using illicit drugs or misusing prescription drugs or nonprescribed drugs. The investigators used somewhat leading questions, such as "In the past three months have you used any of the following to treat your pain or discomfort," the choices being alcohol; illicit drugs such as marijuana, heroin, cocaine; and prescription drugs without a doctor's prescription; or prescription drugs used in larger amounts than prescribed. Of the 589 participants, 87% (95% confidence interval À84-90%) endorsed having chronic pain. The vast majority of these patients (n ¼ 576) had admitted to using illicit drugs, and 51% of this population reported using illicit drugs to treat pain. Of the 121 subjects with prescription drug misuse, 81% stated that they used prescription drugs to treat pain, and 265 subjects who reported any heavy drinking in the past three months 38 % stated that they did so to treat pain. The authors concluded, "Many patients using illicit drugs, misusing prescription drugs and using alcohol reported doing so in order to self-medicate their pain." Mr. Rose interpreted these data as suggesting that poor pain control was common in this cohort and that self-medication to alleviate pain may have "driven apparent substance use disorder." This is an unsubstantiated assumption, and the self-report nature of this study and lack of corroborating information make it less than compelling. Likewise, it is often cited from large data-dredging studies, particularly from Veterans Affairs, large health systems, or insurance claims, that individuals on higher dosing of long-term opioids typically have concomitant psychiatric disorders and substance use disorders. Dr. Sullivan cited a recent study by Quinn et al. [4] in which the investigators evaluated health insurance claims of 10,311,961 patients who filled a prescription for an opioid analgesic. They evaluated how opioid usage differed among patients with and without preexisting psychiatric and behavioral conditions including substance use disorders (SUDs), suicidal behavior, motor vehicle crashes, depression, anxiety, and sleep disorders, and the use of psychoactive medications. They discovered that compared with patients without concomitant psychiatric disorders and medications, those with psychiatric conditions and medications had a greater odds of longterm opioid receipt. This was an elegantly designed study but had significant limitations, which are common in these types of studies. First, as the authors noted, there was no measure of pain intensity or pain duration. Second, the diagnoses of psychiatric conditions, in particular SUDs, were derived via International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes. Who rendered these diagnoses-primary care clinicians or psychiatrists-and how accurate are they? Given the large sample size and the meticulous data analysis, the identified trends between cohorts are very compelling but are susceptible to spurious interpretations as pain severity and duration can cause or V C 2018 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com exacerbate both mood and anxiety disorders and the need for long-term opioid receipt.
Mr. Rose and Dr. Sullivan do agree on several, I think, very important and salient facts: that there is sufficient and compelling evidence that most current heroin users first used prescription opioids, but nonmedically, and that there was a low occurrence of transition to heroin. They also concurred that opioids are rarely the sole cause of fatal overdoses. Dr. Sullivan described the often-cited study on opioid overdoses from a cohort in West Virginia. These frequently-presented data imply that the overdoses were due to opioids alone and that these were patients misusing or abusing prescription opioids. As Dr. Sullivan accurately points out, most of the fatal overdoses were multidrug related and included alcohol, other illicit drugs, and sedatives. These overdoses should be more accurately classified as polysubstance related including opioids, as not to misrepresent the data. Also, the majority of men in this study population used diverted opioids, and most of the woman were found to be doctor shopping [5] , which does not represent the average pain patient using opioids responsibly. Mr. Rose and Dr. Sullivan also agreed that indeed illicit opioids, in particular fentanyl and heroin, are responsible for the majority of the reported opioid-related deaths.
Mr. Rose and Dr. Sullivan differed on the potential efficacy and safety of long-term opioid therapy, with Mr. Rose suggesting that the opioid efficacy trials were biased and methodologically flawed. Dr. Sullivan offered a persuasive argument that there is scant evidence that long-term opioid therapy improves pain, functionality, or quality of life, although it is possible that a well-selected subpopulation of patients with CNMP can benefit from low-dose, long-term opioid therapy. In a recently published article from our laboratory [6] , we prospectively followed, for 12 months, a cohort of 180 patients with CNMP initiating opioid therapy. Patients were excluded from the study if at baseline there was evidence of significant psychopathology or recent history of SUD. Results revealed that there was a low rate of aberrant behavior (<5%) based on urine drug testing and chart review, a substantial number of patients (28%) discontinued opioids due to adverse effects, which is consistent with previous efficacy trials [7] , and a subgroup of patients obtained modest improvement in pain on a low dose of opioids (<20 mgs morphine equivalent daily dose).
Not discussed in these manuscripts are the myriad of other adverse effects of long-term opioid therapy, especially at higher doses that can further erode an individual's quality of life. These include opioid-induced constipation, hyperalgesia, androgen deficiency, sleep disturbance, and physical dependence and tolerance. These common adverse effects are often not discussed with a patient beginning or being maintained on opioid therapy [8] .
Another highly debated topic in the discussion of opioid therapy for CNMP is the accurate prevalence of opioid use disorders (OUD) in patients medically prescribed opioids. Estimates of prescription opioid misuse and abuse range from <1% to 40% [9] [10] [11] [12] [13] [14] . This wide array of estimates in part is due to the paucity of consistent definitions of misuse and abuse across studies and the intrinsic difficulty in diagnosing misuse, abuse, and OUD in patients with CNMP receiving opioid therapy [15] . Two studies evaluated the prevalence of OUD in two large cohorts of patients with CNMP receiving long-term opioid therapy. In both studies, they employed the DSM-5 criteria for diagnosing OUD. Results revealed that the prevalence of lifetime OUD was as high as 41.3% and that 21.7% of one of the study populations met criteria for moderate OUD and 13.2% for severe OUD [13, 14] . These data would suggest that an alarming number of patients on opioid therapy will develop or have developed an OUD. Theoretically the DSM-5 criteria for rendering a diagnosis of OUD are more sensitive than the previous DSM-IV criteria for opioid dependence, as tolerance and dependence are excluded if a patient is prescribed an opioid by a licensed clinician. The DSM-5, like the DSM-IV, contains a number of criteria that patients with CNMP on opioid therapy without an OUD would meet. Vowles et al. [12] conducted a systematic review of the literature and scrutinized studies for quality of design, using accepted standardized definitions for opioid misuse and OUD. He discovered that the rate of misuse ranged from 21.7-29.3% and OUDs from 7.8-11.7% in the pain population. In a thoughtful article by Volkow and McLellan [16] , "Opioid Abuse and Chronic Pain-Misconceptions and Mitigation Strategies," the authors, who are renowned experts in addiction, concurred that the incidence of OUD in patients with CNMP on opioid therapy is low.
Have We Gone Too Far or Not Far Enough?
Historically, our liberal prescribing of opioid analgesics for mild to moderate acute pain and CNMP has led to a deluge of available opioids into the community aquifers and has significantly contributed to the rising rate of opioid-related misuse, abuse and fatalities. For example, a cohort of 250 patients was surveyed after outpatient upper extremity surgery. Results indicated that the patients were prescribed on average 30 tablets of an opioid for postoperative analgesia. Patients used a mean of 10 pills, whereas 19 pills per subject were reported as unused, for a total of 4,639 leftover tablets for the entire cohort. The authors concluded that excess opioid analgesics are made available after elective upper extremity surgery and could potentially become a source for diversion [17] . Opioids are not typically firstline therapy for the majority of CNMP conditions. For example, most guidelines on managing chronic low back pain recommend acetaminophen, nonsteroidal anti-inflammatory drugs, and antidepressants. In the case of fibromyalgia, firstline pharmacologic agents include SNRI antidepressants and antiepileptic medications such as gabapentin and pregabalin. This is not to say that there is no role for opioids in managing pain in patients with CNMP. Opioids can be beneficial in a subgroup of Editorial well-selected, low-risk patients at low doses who have not responded to firstline therapies. This relies on the prescribing clinician having a good working knowledge of risk assessment and monitoring techniques to ensure that the benefits of opioid therapy greatly outweigh the risks.
Conclusion
Mr. Rose and Dr. Sullivan have articulated pertinent issues and raised thought-provoking questions regarding the debate on the efficacy and safety of opioid therapy in managing pain. What seems to be lost in these debates is the equally devastating pain epidemic and the current generally inadequate pain care available to patients. Barriers to improving pain care include:
• Training: Patients with pain, especially chronic pain, are typically complex and present with a number of psychiatric and medical comorbidities. Effectively managing these cases and avoiding initiating or escalating of opioid prescribing relies on clinicians possessing basic core competencies in pain medicine. In a recently published article in Pain Medicine [18] , a group of pain experts evaluated 1,506 questions from the United States Medical Licensing Examination (USMLE) using a novel methodology to characterize questions based on pain core competencies. They discovered that of the 1,506 questions sampled, only 432 (28.7%) identified included the word "pain," and of those only 232 (14.5% of the 1,506 questions) were fully or partially related to pain; the majority of these questions (88%) were related to assessment and not effective and safe management of pain. These results underscore the importance of bolstering pain education in medical school and residency programs to improve pain care.
• Reimbursement for nonopioid therapies and counseling: The majority of state and national guidelines for opioid prescribing recommend that prior to considering opioids, nonopioid therapies should be prescribed, including cognitive behavioral therapy, physical therapy, acupuncture, massage therapy, and psychiatric comanagement. Dr. Sullivan cited a study that revealed that psychotherapeutic and rehabilitative interventions decreased mortality in veterans receiving long-term opioid therapy [19] . Unfortunately, outside of many Veterans Health Administration facilities, these nonopioid services are not easily accessible or are poorly reimbursed. Beleaguered primary care clinicians who care for the majority of patients with complex CNMP typically have neither the time nor the training to effectively manage these patients and are required to make complex decisions about care in a limited amount of time.
The war on the epidemic of opioid misuse, abuse, and opioid-related fatalities and the epidemic of chronic pain will never be won until there is a top-down reformation emphasizing changes in health care education on pain mechanisms and interventions as well as enhanced reimbursement for nonopioid therapies and cognitive medicine.
